Dr. Mark S. Blumenkranz and Mr. Randy Thurman
Presbia Holdings, a medical device company and leader in near vision
restoration, announced today that it has appointed two new members to
serve on its Board of Directors.
“We are very pleased to be adding Dr. Mark S. Blumenkranz and Randy
Thurman to our Board,” said Zohar Loshitzer, Chief Executive Officer of
Presbia. “They strengthen an already stellar group of Directors and
Officers who possess extensive knowledge and expertise in ophthalmology
and medical devices and who will be instrumental in our efforts to
assist patients in improving their near vision.”
Dr. Blumenkranz is the H.J. Smead Professor and Chairman of the
Department of Ophthalmology at Stanford University and is a noted
ophthalmic surgeon. Dr. Blumenkranz focuses primarily on medical and
surgical treatment of a variety of vitreoretinal diseases. He is an
author of more than 100 peer-reviewed publications and book chapters in
the area of vitreoretinal surgery, with special interests in surgical
adjuvant pharmacology and new microsurgical and laser techniques. In
addition to being an associate examiner for the American Board of
Ophthalmology, Dr. Blumenkranz is also a member of the Retina, Vitreous,
Macula and Gonin Societies and is the recipient of various awards in his
field of expertise.
Mr. Thurman is the Executive Chairman of the Board for Cogent HMG, one
of the nation’s largest private hospitalist and intensivist companies.
Mr. Thurman is also an Operating Executive with AEA Investors LP. He has
held many senior positions with other major private and public equity
firms and has over 25 years of healthcare industry experience. He was
the founder, Chairman and CEO of VIASYS Healthcare, Inc. (NYSE:VAS).
Additionally, Mr. Thurman has an extensive background in corporate
governance and has served in various capacities on public company boards.
Detailed biographies of Dr. Blumenkranz and Mr. Thurman can be found on
our website at www.presbia.com.
ABOUT PRESBIA AND THE PRESBIA FLEXIVUE MICROLENS™
Presbia Holdings is a leading ophthalmic-device company focused on the
development of solutions for presbyopia, the age-related loss of the
ability to read or focus on near objects. Chief among these approaches
is the Presbia Flexivue Microlens™, a 3mm-diameter lens that is
implanted in the corneal stroma of the patient’s non-dominant eye using
femtosecond laser technology. The procedure requires no general
anesthesia and typical recovery periods are only a few days. The Presbia
Flexivue Microlens™ solution utilizes standard equipment and ophthalmic
surgical techniques, and requires only minimal additional staff training.
Further information is available at www.presbia.com.
Mary Jensen, 323-860-7482
Source: Presbia Holdings